For research use only. Not for therapeutic Use.
Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases, such as moderate allergic reactions, some autoimmune diseases, and some types of cancer, but it has significant adverse effects. Prednisone reduces mucosal TNF-a production, intestinal permeability and levels of NF-κB expression.
| Catalog Number | A001149 |
| CAS Number | 53-03-2 |
| Synonyms | NA |
| Molecular Formula | C21H26O5 |
| Purity | ≥95% |
| Storage | 3 years -20C powder |
| InChI | InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1 |
| InChIKey | XOFYZVNMUHMLCC-ZPOLXVRWSA-N |
| SMILES | O=C(CO)[C@@]1(O)CC[C@@]([C@]1(C)C2)([H])[C@@]3([H])[C@]([C@](C=C4)(C)C(CC3)=CC4=O)([H])C2=O |
| Reference | </br>1:Does prednisone use or disease activity in pregnant women with rheumatoid arthritis influence the body composition of their offspring? de Steenwinkel FDO, Dolhain RJEM, Hazes JMW, Hokken-Koelega ACS.Reprod Toxicol. 2017 May 9. pii: S0890-6238(17)30232-0. doi: 10.1016/j.reprotox.2017.05.002. [Epub ahead of print] PMID: 28499744 Free Article</br>2:Predictive Value of Clinical Findings and Plasma Biomarkers after 14 Days of Prednisone Treatment for Acute Graft-Versus-Host Disease. McDonald GB, Tabellini L, Storer BE, Martin PJ, Lawler RL, Rosinski SL, Schoch HG, Hansen JA.Biol Blood Marrow Transplant. 2017 May 3. pii: S1083-8791(17)30447-0. doi: 10.1016/j.bbmt.2017.04.029. [Epub ahead of print] PMID: 28478120 </br>3:Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial. Barniol C, Dehours E, Mallet J, Houze-Cerfon CH, Lauque D, Charpentier S.Ann Emerg Med. 2017 May 2. pii: S0196-0644(17)30264-0. doi: 10.1016/j.annemergmed.2017.03.006. [Epub ahead of print] PMID: 28476259 </br>4:Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Safy M, Jacobs J, IJff ND, Bijlsma J, van Laar JM, deHair M; Society for Rheumatology Research Utrecht (SRU)..Ann Rheum Dis. 2017 Apr 27. pii: annrheumdis-2016-210647. doi: 10.1136/annrheumdis-2016-210647. [Epub ahead of print] PMID: 28450312 </br>5:A Retrospective Study on Mycophenolic Acid Drug Interactions: Effect of Prednisone, Sirolimus, and Tacrolimus With MPA. Alvarez-Elías AC, Yoo EC, Todorova EK, Singh RN, Filler G.Ther Drug Monit. 2017 Jun;39(3):220-228. doi: 10.1097/FTD.0000000000000403. PMID: 28437284 </br>6:Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B.J Clin Oncol. 2017 Apr 20:JCO2017726984. doi: 10.1200/JCO.2017.72.6984. [Epub ahead of print] PMID: 28426350 </br>7:Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Kessler ER, Gao D, Flaig TW, Breaker K, Wold M, Wacker M, Lam ET.Ann Oncol. 2017 Mar 1;28(3):668. doi: 10.1093/annonc/mdw674. No abstract available. PMID: 28426121 </br>8:A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. van Dodewaard-de Jong JM, de Klerk JMH, Bloemendal HJ, Oprea-Lager DE, Hoekstra OS, van den Berg HP, Los M, Beeker A, Jonker MA, O/’Sullivan JM, Verheul HMW, van den Eertwegh AJM.Eur J Nucl Med Mol Imaging. 2017 Apr 18. doi: 10.1007/s00259-017-3673-9. [Epub ahead of print] PMID: 28421240 </br>9:Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. Cutolo M, Hopp M, Liebscher S, Dasgupta B, Buttgereit F.RMD Open. 2017 Mar 17;3(1):e000426. doi: 10.1136/rmdopen-2016-000426. eCollection 2017. PMID: 28405475 Free PMC Article</br>10:A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Kim MK, Kim K, Min CK, Kwak JY, Bae SB, Yoon SS, Lee JJ, Kim KH, Nam SH, Mun YC, Kim HJ, Bae SH, Shin HJ, Lee JH, Park JS, Jeong SH, Lee MH, Kim YS, Lee HS, Park KW, Lee WS, Lee SM, Lee JO, Hyun MS, Jo DY, Lim SN, Lee JH, Cho DY, Do YR, Kim JA, Park SK, Kim JS, Kim SJ, Kim H, Yi HG, Moon JH, Choi CW, Kim SH, Joo YD, Kim HG, Kim BS, Park MR, Song MK, Kim SY.Oncotarget. 2017 Apr 3. doi: 10.18632/oncotarget.16790. [Epub ahead of print] PMID: 28402945 Free Article |
